TLDR The treatment was ineffective in humans.
The study investigated the efficacy of CUR61414, a topical inhibitor of the Hedgehog signaling molecule Smoothened, in treating basal cell carcinomas (BCC). Preclinical tests on mice showed that CUR61414 significantly inhibited Hedgehog signaling, blocked hair follicle growth, and reduced BCC size. However, in a phase I clinical trial involving human subjects with superficial or nodular BCCs, the treatment showed no clinical activity. The results underscore the difficulties in translating successful preclinical findings into effective human treatments.
63 citations,
May 2011 in “Clinical cancer research” The topical inhibitor CUR61414 was not effective in treating basal cell carcinoma in human trials.
15 citations,
October 2014 in “Journal of Investigative Dermatology” New treatments targeting the Hedgehog pathway can help treat advanced skin cancer but may have side effects and their effectiveness in early stages is unknown.
36 citations,
September 2009 in “Journal of Cellular and Molecular Medicine” New treatments targeting skin stem cells show promise for skin repair, anti-aging, and cancer therapy.
1 citations,
September 2011 in “UHOD : Uluslararası hematoloji - onkoloji dergisi” Looking at tissue characteristics isn't reliable for telling apart basal cell carcinoma from certain benign skin tumors.
May 2015 in “Actas Dermo-Sifiliográficas” A young man was unexpectedly diagnosed with basal cell carcinoma after a scalp examination and confocal microscopy.
